Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. The Company's lead product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Tipifarnib is a new chemical entity, or NCE, and a member of a class of product candidates called farnesyl transferase inhibitors, or FTIs. Protein farnesylation is a key cell signaling process implicated in various cancer processes, including survival, growth and proliferation of tumor cells. 

Type
Public
HQ
San Diego, US
Founded
2007
Size (employees)
30 (est)
Kura Oncology was founded in 2007 and is headquartered in San Diego, US
Report incorrect company information

Kura Oncology Office Locations

Kura Oncology has an office in San Diego
San Diego, US (HQ)
125 11119 N Torrey Pines Rd
Show all (1)
Report incorrect company information

Kura Oncology Financials and Metrics

Kura Oncology Financials

USD

Net income (FY, 2017)

(35.4 m)

Market capitalization (23-Apr-2018)

363.5 m

Cash (31-Dec-2017)

11.4 m

EV

359.1 m
Kura Oncology's current market capitalization is $363.5 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

9.4 m

R&D expense

25.1 m

Operating expense total

36.1 m

Interest expense

888 k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

1.5 m63 k2.4 m1.8 m1.7 m2.1 m2.2 m

R&D expense

3.3 m3 k3.6 m4 m4.3 m5.2 m5.2 m

Operating expense total

5.9 m66 k7 m6.8 m7.1 m7.7 m7.9 m9.5 m

Interest expense

42 k42 k42 k189 k194 k203 k209 k226 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

6.6 k5.6 k15.4 m9.7 m11.4 m

Accounts Receivable

92.4 m

Inventories

693 k725 k

Current Assets

86.9 m68.8 m94.6 m
Quarterly
USDQ3, 2017

Inventories

909 k

Accounts Payable

6.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.6 k)(30.7 k)(3.7 m)(27.6 m)(35.4 m)

Depreciation and Amortization

1 k31 k30 k

Inventories

(42 k)(32 k)

Accounts Payable

(1.5 k)2.1 k833 k471 k3.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.6 m)(66 k)(6.6 m)(6.7 m)(6.9 m)(7.5 m)(9.3 m)

Inventories

909 k

Accounts Payable

650 713 8.2 k10.7 k2.5 m3.7 m3.1 m3.3 m4.2 m3.7 m4.2 m6.2 m
USDY, 2017

EV/CFO

-12.6 x

Financial Leverage

1.2 x
Show all financial metrics

Kura Oncology Operating Metrics

FY, 2016

Phase II Trials Products

1

Preclinical Phase Products

2
Show all operating metrics
Report incorrect company information